14 January, 2016, 04:32 AM
Basic Peptide Overview
GHRP-6: Growt-hormon releasing peptide 6
The principal use of GHRP-6 is to provide increased GH levels, which also results in increased IGF-1 levels. This aids fat loss and in some instances aids muscle gain as well. Generally, GHRP use is chosen as an alternate to GH use, and only rarely is combined with GH.
GHRP-6 and all GHRP’s are mimetics of ghrelin, a hormone produced by cells of the stomach in response to a fasted condition, including brief fasts. Ghrelin and ghrelin mimetics work by activating the ghrelin receptor, also called the growth hormone secretagogue receptor (GHS-R1a). Elevated ghrelin levels act towards increasing GH levels by stimulation of ghrelin receptors in the pituitary.
Ghrelin er også kalt sulthomonet så mange brukere opplever et betydelig forstørret behov for mat som for mange vil være en meget positiv side-effekt
Effekt: Abstract
We have recently reported oral and parenteral bioactivity for a new GH-releasing peptide, hexarelin. In the present study, we have examined the neuroendocrine mechanism by which hexarelin and GHRP-6, two GH-releasing peptides, mediate their actions. Although previous studies have looked at the role of growth hormone-releasing hormone (GHRH) and somatostatin in regulating the action of GHRP-6 in culture and in stressed animals, our study looked at the role of both somatostatin and GHRH in regulating the action of hexarelin as well as GHRP-6 in conscious and freely-moving, nonstressed rats. Adult male rats, prepared with indwelling jugular catheters, were pretreated i.v. with either control antiserum (CTLas), growth hormone-releasing hormone antiserum (GHRHas), somatostatin antiserum (SSas), or both GHRHas and SSas. Animals were then treated i.v. with 25 micrograms/kg of either hexarelin or GHRP-6 4 h after i.v. antisera pretreatment. Blood samples were collected every 20 min for the 3 h prior to peptide treatment and at 5, 10, 15, 20, 40 and 60 min following hexarelin or GHRP-6 injection. The peak plasma GH responses in rats pretreated with CTLas were 552 +/- 125 ng/ml following hexarelin administration and 386 +/- 132 ng/ml following GHRP-6 administration. Rats pretreated with SSas exhibited peak GH responses following hexarelin or GHRP-6 of 702 +/- 115 and 312 +/- 42 ng/ml, respectively. These plasma GH responses were similar to those observed in the CTLas-pretreated animals.
Dosing: When dosing, an appropriate volume will be drawn from the vial with (typically) an insulin syringe, according to the desired dose and the concentration of the preparation. In the above example, a 100 mcg dose would require only 0.05 mL, or “5 IU” as marked on an insulin syringe. A 300 mcg would require 0.15 mL, or “15 IU” as marked on an insulin syringe.
Injection may be subcutaneous, intramuscular, or intravenous according to personal preference.
Dosing will ordinarily be at least twice per day and preferably 3x/day for best effect, taken at least 30-60 minutes before a meal and at a time of non-elevated blood sugar (in other words, after blood sugar has had time to fall since the most recent meal.) The amount taken generally will be from 50-300 mcg at a time. When using a GHRH along with GHRP-6, dosing should be reduced to 50-100 mcg at a time.
Other activities of ghrelin, and potentially of GHRP-6
Ghrelin has many activities in the body besides stimulating GH release. It stimulates appetite, is cardioprotective, can help protect cells against oxidative damage, can reduce inflammation and promote healing, and can promote fat-burning in muscle. There is also some effect on increase in cortisol production via increase in ACTH, and increase in prolactin. However, where the activity of ghrelin is comparable to that which ordinarily occurs during fasting, effects on cortisol and prolactin likewise are comparably only to that experienced while fasting.
Ghrelin itself so far as I know has not been used as a performance-enhancing drug. In contrast, experience with GHRP’s is quite extensive. GHRP-6 in particular has in many cases been effective in treating tendonitis, which may well be due to its activity at the ghrelin receptor.
Conclusion
GHRP-6 can effectively provide substantial increases in GH production. It’s typically taken 2-3 times per day by injection at times when blood sugar is not elevated. Cost is generally moderate. The only common potential adverse side effect is increased hunger. Common alternates include GHRP-2, hexarelin, ipamorelin, or GH itself. GHRP-6 also may provide benefits which GH does not, via its action at the ghrelin receptor in various tissues of the body.
Legger til at GHRP bør kombineres med GHRH (like Mod-Grf) for 1+2 = 4 effekt
Gjør dette og førlg normaldosering vil resultatene snakke for seg selv etter egen erfaring.
Usikker på hvordan MK-677 vil påvirke en slik cycle men vil undersøke nærmerer
GHRP-6: Growt-hormon releasing peptide 6
The principal use of GHRP-6 is to provide increased GH levels, which also results in increased IGF-1 levels. This aids fat loss and in some instances aids muscle gain as well. Generally, GHRP use is chosen as an alternate to GH use, and only rarely is combined with GH.
GHRP-6 and all GHRP’s are mimetics of ghrelin, a hormone produced by cells of the stomach in response to a fasted condition, including brief fasts. Ghrelin and ghrelin mimetics work by activating the ghrelin receptor, also called the growth hormone secretagogue receptor (GHS-R1a). Elevated ghrelin levels act towards increasing GH levels by stimulation of ghrelin receptors in the pituitary.
Ghrelin er også kalt sulthomonet så mange brukere opplever et betydelig forstørret behov for mat som for mange vil være en meget positiv side-effekt
Effekt: Abstract
We have recently reported oral and parenteral bioactivity for a new GH-releasing peptide, hexarelin. In the present study, we have examined the neuroendocrine mechanism by which hexarelin and GHRP-6, two GH-releasing peptides, mediate their actions. Although previous studies have looked at the role of growth hormone-releasing hormone (GHRH) and somatostatin in regulating the action of GHRP-6 in culture and in stressed animals, our study looked at the role of both somatostatin and GHRH in regulating the action of hexarelin as well as GHRP-6 in conscious and freely-moving, nonstressed rats. Adult male rats, prepared with indwelling jugular catheters, were pretreated i.v. with either control antiserum (CTLas), growth hormone-releasing hormone antiserum (GHRHas), somatostatin antiserum (SSas), or both GHRHas and SSas. Animals were then treated i.v. with 25 micrograms/kg of either hexarelin or GHRP-6 4 h after i.v. antisera pretreatment. Blood samples were collected every 20 min for the 3 h prior to peptide treatment and at 5, 10, 15, 20, 40 and 60 min following hexarelin or GHRP-6 injection. The peak plasma GH responses in rats pretreated with CTLas were 552 +/- 125 ng/ml following hexarelin administration and 386 +/- 132 ng/ml following GHRP-6 administration. Rats pretreated with SSas exhibited peak GH responses following hexarelin or GHRP-6 of 702 +/- 115 and 312 +/- 42 ng/ml, respectively. These plasma GH responses were similar to those observed in the CTLas-pretreated animals.
Dosing: When dosing, an appropriate volume will be drawn from the vial with (typically) an insulin syringe, according to the desired dose and the concentration of the preparation. In the above example, a 100 mcg dose would require only 0.05 mL, or “5 IU” as marked on an insulin syringe. A 300 mcg would require 0.15 mL, or “15 IU” as marked on an insulin syringe.
Injection may be subcutaneous, intramuscular, or intravenous according to personal preference.
Dosing will ordinarily be at least twice per day and preferably 3x/day for best effect, taken at least 30-60 minutes before a meal and at a time of non-elevated blood sugar (in other words, after blood sugar has had time to fall since the most recent meal.) The amount taken generally will be from 50-300 mcg at a time. When using a GHRH along with GHRP-6, dosing should be reduced to 50-100 mcg at a time.
Other activities of ghrelin, and potentially of GHRP-6
Ghrelin has many activities in the body besides stimulating GH release. It stimulates appetite, is cardioprotective, can help protect cells against oxidative damage, can reduce inflammation and promote healing, and can promote fat-burning in muscle. There is also some effect on increase in cortisol production via increase in ACTH, and increase in prolactin. However, where the activity of ghrelin is comparable to that which ordinarily occurs during fasting, effects on cortisol and prolactin likewise are comparably only to that experienced while fasting.
Ghrelin itself so far as I know has not been used as a performance-enhancing drug. In contrast, experience with GHRP’s is quite extensive. GHRP-6 in particular has in many cases been effective in treating tendonitis, which may well be due to its activity at the ghrelin receptor.
Conclusion
GHRP-6 can effectively provide substantial increases in GH production. It’s typically taken 2-3 times per day by injection at times when blood sugar is not elevated. Cost is generally moderate. The only common potential adverse side effect is increased hunger. Common alternates include GHRP-2, hexarelin, ipamorelin, or GH itself. GHRP-6 also may provide benefits which GH does not, via its action at the ghrelin receptor in various tissues of the body.
Legger til at GHRP bør kombineres med GHRH (like Mod-Grf) for 1+2 = 4 effekt
Gjør dette og førlg normaldosering vil resultatene snakke for seg selv etter egen erfaring.
Usikker på hvordan MK-677 vil påvirke en slik cycle men vil undersøke nærmerer
Grønningstråd
https://roidboard.to/showthread.php?tid=9742
https://roidboard.to/showthread.php?tid=9742
https://roidboard.to/showthread.php?tid=9742
https://roidboard.to/showthread.php?tid=9742